Q1 2025 Vicarious Surgical Inc Earnings Call

Yeah.

Nadia: Hello everyone and welcome to the Vicarious Surgical's 2025 First Quarter Earnings. My name is Nadia and I'll be coordinating the call today. If you would like to ask a question please press star followed by one on your telephone keypad.

Speaker Change: Hello, everyone and welcome to the caller is surgical was 2025 last quarter, adding co. My name is not yet and I'll be coordinating the call today if.

Speaker Change: If you would like to ask a question. Please press star followed by one on the telephony Pat.

Webb Campbell: I will now hand over to your host, Webb Campbell, Investor Relations, to begin. Webb, please go ahead. Good afternoon.

Speaker Change: Now I know what your highest web Campbell Investor Relations to begin Weber. Please go ahead.

Speaker Change: Good afternoon today after market close by carrier surgical released financial results for the three months ended March 31 2025.

Webb Campbell: Today, after market closed, Vicarious Surgical released financial results for the three months ended March 31, 2025. A copy of the press release is available on the company's website.

Speaker Change: The press release is available on the Companys website.

Webb Campbell: Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities law, which are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to Obtaining approval for the vicarious surgical system and the timing of any such approval or operating trends and future financial performance, expense management, market opportunity, and commercialization are based upon current estimates and various assumptions.

Speaker Change: Before we begin I'd like to remind you that management will make statements. During this call that include forward looking statements within the meaning of federal Securities Law, which are made pursuant to the safe Harbor provision of the private Securities Litigation Reform Act of 1995.

Speaker Change: Any statements contained in this call that relate to expectations or predictions of future events results or performance are forward looking statements all forward looking statements, including without limitation those relating to <unk>.

Speaker Change: Obtaining approval for the bi curious surgical system and the timing of any such approval.

Speaker Change: Our operating trends and future financial performance expense management market opportunity and commercialization are based upon current estimates and various assumptions.

Webb Campbell: These statements involve material risks and uncertainties that could cause actual results to differ or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

Speaker Change: These statements involve material risks and uncertainties that could cause actual results to differ or events to materially differ from those anticipated or implied by these forward looking statements. Accordingly, you should not place undue reliance on these statements.

Webb Campbell: For a list and description of these risks and uncertainties associated with our business, please refer to the risk factors set in our Securities and Exchange Commission filings, including in our most recent Form 10-K and Form 10-Q.

Speaker Change: For a list and description of these risks and uncertainties associated with our business. Please refer to the risk factors in our Securities and Exchange Commission filings, including in our most recent Form 10-K and Form 10-Q.

Webb Campbell: This conference call contains time sensitive information and is accurate only as of the live broadcast today, May 12, 2025. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether based on new information, future events, or otherwise.

Vicarious Surgical: This conference call contains time sensitive information and is accurate only as of the live broadcast today May 12, 2025, vicarious surgical disclaims any intention or obligation except as required by law to update or revise any financial projections or forward looking statements, whether based on new information future events or otherwise.

Adam Sachs: Now, I'll hand the call over to Adam Sachs, co-founder and CEO, for prepared remarks. Thanks, Webb. Good afternoon, everyone, and thank you for joining Vicarious Surgical's first quarter 2025 earnings. I'm pleased to be here today alongside Sarah Romano, our Chief Financial Officer.

Adam: Now I'll hand, the call over to Adam <unk> co founder and CEO.

Vicarious Surgical: We're prepared remarks Adam.

Adam: Thanks, a lot.

Adam: Good afternoon, everyone and thank you for joining by carrier Surgical's first quarter 'twenty four 'twenty five earnings call I'm pleased to be here today, alongside Sarah Romano, our Chief Financial Officer.

Adam Sachs: We're especially delighted to have Sarah with us for her first earnings call as an official member of the Vicarious team, having joined us at the beginning of April. Sarah begins, excuse me, brings decades of financial leadership experience and substantial knowledge from prior CFO positions at innovative businesses in the healthcare sector. She has run successful fundraising activities, M&A initiatives, and operations strategies in her career.

Adam: We're especially delighted to have Sara with us for her first earnings call as an official member of the vicarious team having joined US at the beginning of April.

Adam: Sarah begins excuse me brings decades of financial leadership experience and substantial knowledge from prior CFO positions at innovative businesses and the health care sector.

Adam: She has run successful fund raising activities M&A initiatives and operations strategies in her career.

Adam Sachs: Turning to our recent business progress, it is truly an exciting time at Vicarious Surgical. For the last decade, our vision has been to revolutionize robotic surgery by overcoming the limitations inherent in open, laparoscopic, and existing robotic approaches. After years of dedicated effort in developing our proprietary decoupled actuating technology and meticulously refining our surgical system to enable minimally invasive procedures through a single small incision, we are just a few quarters away from our biggest milestone yet, our first clinical patient. We anticipate 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of our single-port surgical system.

Adam: Turning to our recent business progress it is truly an exciting time at vicarious surgical for the last decade, our vision has been to revolutionize robotic surgery by overcoming the limitations inherent in open laparoscopic and existing robotic approaches.

Adam: After years of dedicated effort in developing a proprietary decoupled actuated technology and meticulously refining our surgical system to enable minimally invasive procedures through a single small incision. We are just a few quarters away from our biggest milestone yet our first clinical patients.

We anticipate 2025 will be the year vicarious surgical evolved into a clinical stage company and demonstrates the immense value of our single port surgical system.

Adam Sachs: For the current year, our efforts are directed toward the precise and timely execution of all critical intermediate steps essential for our success in the clinic. These include, first, the expansive inventory build-out of instrument arms, cameras, and capital equipment to support our schedule of rigorous testing. Second, the successful completion of all essential performance and safety testing with our surgical system, such as sterility, biocompatibility, and electromagnetic compatibility. Third, securing appropriate in-country regulatory approvals to advance clinical work at our respective planned sites. In the first quarter, we successfully built our first patient cart and surgeon consul for formal preclinical testing and have since begun system integration as well as the construction of our second surgeon consul and patient cart that will be utilized in our first human case.

Adam: For the current year, our efforts are directed toward the precise and timely execution of all critical intermediate steps are central for our success in the clinic.

Adam: These include first the expansive inventory build out of instrument arms cameras and capital equipment to support our schedule of rigorous testing.

Adam: The successful completion of all the central performance in safety testing with our surgical system, such as sterility biocompatibility and electromagnetic compatibility.

Adam: Started securing appropriate in country regulatory approvals to advance clinical work at our respective planned sites.

Adam: In the first quarter, we successfully built our first patient card and surgeon console for formal preclinical testing and have since begun system integration as well as the construction of our second surgeon console and patient part that will be utilized in our first human cases.

Adam Sachs: Further, our initial instrument sets have completed production and have completed bioburden review. With these results in hand, we expect to begin initial biocompatibility and sterility testing on new inventory momentarily, as well as to send additional instruments for sterilization and subsequent essential performance and safety tests.

Adam: Further our initial attack instrument sets have completed production and have completed bio burden review.

Adam: With these results in hand, we expect to begin initial biocompatibility and sterility testing on new inventory momentarily as well as the sand additional instruments for sterilization and subsequent a central performance and safety testing.

Adam Sachs: On the clinical side, we are preparing for our first human cases. We expect to treat a handful of patients at a few sites. The end point for these initial patients will align with that of our pivotal trial, focusing on the surgeon's ability to successfully complete the intended ventral hernia repair. We continue to advance through the approval process required to perform our first clinical procedure. We are maintaining close collaboration with reviewers in this process, providing necessary information for their review of the study design, methodology, and procedure.

Adam: On the clinical side, we are preparing for our first human cases, we expect to treat a handful of patients at a few sites. The endpoint for these initial patients will all align with that of our pivotal trial focusing on the surgeon's ability to successfully complete the intended ventral hernia repair.

Adam: We continue to advance through the approval process required to perform our first clinical procedures. We are maintaining close collaboration with the reviewers and this process providing necessary information for their review of the study design methodology and procedures.

Adam Sachs: Beyond our development and clinical progress in the quarter, we are also pleased to announce our latest strategic hospital system partnership with UMass Memorial Medical Center, a premier healthcare system in the greater Boston area and clinical partner of the esteemed University of Massachusetts Chan Medical School. This collaboration will concentrate on optimizing critical elements of implementing a robotic system, including refining paraoperative practices, enhancing surgeon education through mentorship and system testing, and establishing ambassadorship activities to drive best practices and adoption of our version 1.0 system. UMass Memorial's regional prominence, academic focus, and close proximity to our WALPAM headquarters make them an invaluable partner as we work to optimize the integration of our technology into hospital environments.

Adam: Beyond our development and clinical progress in the quarter. We were also pleased to announce our latest strategic hospital system partnership with Umass Memorial Medical Center, a premier health care system in the greater Boston area and clinical partner of the esteemed University of Massachusetts Chan Medical School.

Adam: This collaboration will concentrate on optimizing critical elements of implementing a robotic system, including refining parent operative practices enhancing surgeon education through Mentorship and system testing and establishing ambassadorship activities to drive best practices and adoption of our version one point of system.

Adam: Umass Memorial regional prominence academic focus in close proximity to our Waltham headquarters makes him an invaluable partner as we work to optimize the integration of our technology into hospital environments.

Adam Sachs: This collaboration adds to our strong set of existing partnerships with several leading healthcare institutions and providers, including HCA Healthcare, University Hospitals, Pittsburgh Creates, Intermountain Health, and LSU Health New Orleans. These strategic collaborations, combined with the unwavering commitment of our team, give us a strong conviction in our capability to realize our corporate mission and achieve our objectives for the year.

Adam: This collaboration adds to our strong set of existing partnerships with several leading health care institutions and providers, including HCA healthcare University hospitals, Pittsburgh creates Intermountain health and <unk> health in New Orleans. These.

Adam: These strategic collaborations combined with the unwavering commitment of our team give us a strong conviction in our capability to realize our corporate mission and achieved our objectives for the year.

Adam Sachs: We are increasingly optimistic that the progress made in the first quarter will enable us to showcase the groundbreaking value of our V1.0 system in a clinical setting later this year, a pivotal moment which we are keenly focused on.

Adam: We are increasingly optimistic that the progress made in the first quarter will enable us to showcase the groundbreaking value of our V. One point out of a system in a clinical setting later this year, a pivotal moment, which we are keenly focused on.

Sarah Romano: With that, I'll now turn the call over to Sarah to review our first quarter financial results. Thank you, Adam. Total operating expenses for the first quarter of 2025 were $15.7 million, a 2% decrease compared to $16.1 million in the first quarter of 2024. R&D expenses for the first quarter of 2025 were $9.4 million, compared to $10 million in the first quarter of 2024. General and Administrative expenses for the first quarter of 2025 were $5.3 million, compared to $5 million in the first quarter of 2024. And first quarter 2025 sales and marketing expenses were $1 million, essentially flat from the prior year.

Adam: With that I'll now turn the call over to Sarah to review, our first quarter financial results.

Sarah Romano: Thank you Adam.

Sarah Romano: Total operating expenses for the first quarter of 2025 were $15 7, million% to 2% decrease compared to $16 1 million in the first quarter 2024.

Sarah Romano: R&D expenses for the first quarter of 2025 were $9 4 million compared to $10 million in the first quarter of 'twenty four.

Sarah Romano: General and administrative expenses for the first quarter of 'twenty, five or $5 3 million compared to $5 million in the first quarter of 'twenty four.

And first quarter 2025 sales and marketing expenses were $1 million essentially flat from the prior year period.

Sarah Romano: Further, adjusted net loss for the first quarter of 2025 was $15.3 million, or $2.58 per share, as compared to $15.1 million, or also $2.58 per share, in the first quarter of 2024. Gap net loss for the first quarter of 25 was $15.4 million, or $2.60 per share. This compares to a net loss of $17 million, or $2.90 per share, in the first quarter of 2015.

Sarah Romano: Further adjusted net loss for the first quarter of 2025 was <unk> 3 million or $2 58 per share as compared to $15 1 million or also $2.50 per share in the first quarter of 'twenty 'twenty four.

Sarah Romano: GAAP net loss for the first quarter of 25 to $15 4 million or $2 60 per share.

Sarah Romano: This compares to a net loss of $17 million or $2 97 per share in the first quarter of 'twenty four.

Sarah Romano: For a reconciliation of all non-GAAP measures to GAAP, please review our earnings project. We ended the first quarter of this year with approximately $37 million of cash, cash equivalents, and short-term investments on our balance sheet. This represents our first quarter cash burn rate of approximately $12 million. We continue to expect full year 2025 cash burn to be approximately $50 million, and we remain committed to disciplined capital allocation.

Sarah Romano: For a reconciliation of all non-GAAP measures to GAAP. Please review our earnings press release.

Sarah Romano: We ended the first quarter of this year with approximately $37 million of cash cash equivalents and short term investments on our balance sheet.

Sarah Romano: Represents a first quarter cash burn rate of approximately $12 million.

Sarah Romano: We continue to expect full year 2025 cash burn to be approximately $50 million and we remain committed to disciplined capital allocation.

Sarah Romano: 2025 is off to a strong start, and we look forward to updating you as we progress with our business initiative in the coming quarter.

Sarah Romano: 2025 is off to a strong start and we look forward to updating you as we progress with our business initiatives in the coming quarters.

Adam Sachs: With that, I will turn the call back to Adam for closing remarks. Thanks, Sarah. Vicarious Surgical is on course for a transformative 2025. The team's solid first quarter performance puts us firmly on the path to achieving our first major clinical milestone later this year. Our achievements are, as ever, a direct result of the unwavering dedication of our team coupled with the invaluable support of our investors and stakeholders. Thank you for your continued belief in Vicarious Surgical.

Adam: With that I will turn the call back to Adam for closing remarks.

Adam: Thanks Sarah.

Speaker Change: Terry surgical is on course for a transformative 2025, the team's solid first quarter performance puts us firmly on the path to achieving our first major clinical milestone later this year.

Speaker Change: Our achievements achievements are as ever a direct result of the unwavering dedication of our team coupled with invaluable support of our investors and stakeholders.

Speaker Change: For your continued belief and vicarious surgical.

Adam Sachs: And thank you to everyone who joined the call today. We appreciate your support and look forward to updating you on our continued progress.

Speaker Change: And thank you to everyone who joined the call today. We appreciate your support and look forward to updating you on our continued progress.

Nadia: Nadia, we're ready for questions. Thank you. If you would like to ask a question, please press star followed by one on your telephone keypad. If you would like to remove your question, please press star followed by two.

Speaker Change: Now we're ready for questions.

Speaker Change: Thank you and if he would like to ask a question. Please press star followed by one on your telephone keypad.

Speaker Change: If you would like to me feel question that pays press star followed by case.

Nadia: When the parent asks your question, please enter your phone as unmuted locally.

Speaker Change: When the parents all she'll question picking channel side of the mutual lately.

Ryan Zimmerman: Our first question goes to Ryan Zimmerman of BTIG. Ryan, please go ahead.

Speaker Change: Our final question guys, you're buying it in and then B T. I G. Find please go ahead.

Izzy: Hi everyone, this is Izzy on for Ryan. Thank you for taking the questions. And Sarah, congrats on your new role here.

Speaker Change: Hi, everyone. This is <unk> on for Ryan. Thank you for taking the questions and congrats on your new role here.

Sarah Romano: Just to start out, given your current cash balance right now and the expectations for burning through the year, I was just curious what assurances you can give to investors about your continued ability to fund operations. So hi, nice to hear from you. Thank you for the question. So our main focus is on discipline spending, on ensuring that we stay within budget, while also ensuring that we produce a safe and effective product. So we're reviewing all costs, ensuring that our cash is being used in the most effective way possible. Additionally, we are thinking strategically about our financing.

Speaker Change: Just to start out given your current cash balance right now and the expectations for bearing through the year I was just curious what assurances you can give to investors about your.

Speaker Change: Continued ability to fund operations.

Speaker Change: Okay.

Speaker Change: So hi, <unk> nice to hear from you and thank you for the question. So our main focus is on disciplined spending on ensuring that we stay within budget. While also ensuring that we produce is safe and effective product.

Speaker Change: So we're reviewing all costs, ensuring that our cash is being used most effectively profitable.

Speaker Change: Additionally, we are thinking strategically about our our financing them. We're currently evaluating all options that are available to us and.

Sarah Romano: We're currently evaluating all options that are available to us. We do have a very supportive insider base. We believe it will be very supportive going forward as well, and hopefully some new investors coming to the table as well. With several upcoming exciting milestones ahead, we're hoping to structure a financing around these. So I think we're all very optimistic here with our ability to finance the company. That's helpful. Thank you, Sarah.

Speaker Change: We do have a very supportive insider base, we believe they'll be very supportive going forward as well and hopefully some new investors coming coming to the table as well.

Speaker Change: With several upcoming exciting milestones ahead mm, we're hoping a structure a financing around me. So I think we're all very optimistic here, but.

Speaker Change: With our ability to finance the company.

Speaker Change: Yeah.

Speaker Change: Got it that's helpful. Thank you Sarah and as we think of it less supply just curious if you guys are how you're feeling about your ability to supply any remaining components for the do you want to build.

Sarah Romano: And as we think about the supply, just curious if you guys are how you're feeling about your ability to supply any remaining components for the V1.0 build, anything that we should be aware of there. Thank you for taking the question. Yeah, so, you know, last quarter, we did note some challenges with our supply chain. It's obviously quite a complex supply chain for a fairly complex system overall. And that being said, we've managed this effectively. And we have not seen any, you know, further changes or adjustments in our schedule as a result of supply. So I would say at the moment, we're feeling quite good about our supply chain.

Speaker Change: Anything that we should be aware of there. Thank you for taking the questions.

Speaker Change: Yeah. So last quarter, we did note some challenges with our supply chain. It's obviously quite a complex supply chain for a fairly complex system overall.

Speaker Change: Being said we are.

Speaker Change: Manage this effectively and we have not seen any further.

Speaker Change: Changes or adjustments in our schedule as a result of supply. So I would say at the moment, we're feeling quite good about our supply chain, we have a pretty amazing team.

Sarah Romano: We have pretty amazing team that manages the entire supply chain for our business. And they've been able to do so effectively in the last quarter.

Speaker Change: That manages the entire supply chain for our business and they've been able to do so effectively in the last quarter.

Sarah Romano: Got it.

Speaker Change: Got it thank you for taking the questions.

Sarah Romano: Thank you for taking the questions.

Sarah Romano: Thank you.

Speaker Change: Thank you.

Speaker Change: Thank you as a reminder, if you would like to ask a question. Please press star followed by one on your telephone keypad.

Nadia: As a reminder, if you would like to ask a question, please press star followed by one on your telephone keypad.

Josh Jennings: And the next question goes to Josh Jennings of TD Kevin. Josh, please go ahead.

Speaker Change: And the next question go to Josh Jennings with PD and then Josh. Please go ahead.

Eric: Hi, this is Eric on for Josh. Thank you for taking the question. I wanted to ask you about the technical dossier submission that should be unlocking your ability to conduct first patient testing. I was just hoping for a little more detail on the review timeline expectations, but I think you said in the past that it could be a few months, and I was just hoping we could talk through the assumption there and where it comes from, and also if that factors in some potential questions that you could be receiving from the agency. For more information visit www.FEMA.gov Yeah, thanks, Eric.

Speaker Change: Hi, This is Eric on for Josh. Thank you for taking the question I wanted to ask you about the technical dossier submission that should be unlocking your ability to conduct a first patient testing I was just hoping for a little more detail on the review timeline expectations.

Speaker Change: I think you've said in the past, but it could be a few months and I was just hoping we could talk through the assumption there and where it comes from and also if that factors in some potential questions that you could be receiving from the agency.

Speaker Change: Yeah. Thanks, Eric I appreciate the question. So overall, we're looking you know are around mid this year at filing our technical dossier are in country in order to do these first clinical patients.

Eric: I appreciate the question. So overall, we're looking, you know, around mid this year at filing our technical dossier in-country in order to do these first clinical patients. This includes a ton of information, all of the safety testing and performance data that's required to use our system in the first human cases later this year. So we're really excited about this. We've made a set of assumptions that enable us to do these first patients later this year, and that's based on a number of assumptions around other companies with similar products, similar levels of complexity that have filed in similar countries or actually the same country or the same agency in the last year or two.

Speaker Change: <unk> includes a ton of information all of the safety testing and performance data that's required to use our system and in the first human cases later this year. So what we're really excited about this.

Speaker Change: We've made a set of assumptions that enable us to do at these first patients later this year.

Speaker Change: And that's based on a number of assumptions around other companies with similar products similar levels of complexity that have filed and are in similar countries salary actually the same country with the same agency in the last year or two so we feel fairly confident in these assumptions we have that does.

Eric: So we feel fairly confident in these assumptions we have that does bake in some time to go back and forth, hence why, you know, we're filing in the middle of this year and doing those first cases later. Understood. That makes sense.

Speaker Change: Taken some time to go back and forth. Hence why you know we're filing in the middle of this year and doing those first cases later this year.

Speaker Change: Understood that makes sense and then on the hospital partners that you've been announcing and congrats on the recent announcement today.

Eric: And then on the hospital partners that you've been announcing, and congrats on the recent announcement today, to what extent could they be additive to your development process as we stand right now?

Speaker Change: To what extent could they be additive to your development process as we stand right now or is that really something that once you reach commercial stage.

Adam Sachs: Or is that really something that once you reach commercial stage, the benefit of those partners will become evident? So first, the second part of your question there 100%. I mean, we are working with these partners and they are working with us because they're excited about what we're doing. And they want to see it in the operating room and be able to use it in the operating This is a market that is 96% white space, that has incredible opportunity and not nearly enough surgical robotics or robots out in the field today, which gives these hospital systems the opportunity and the availability to purchase our system when we're on market because of its differentiation and the promise of visualization, dexterity, sensing capabilities and ability to operate.

Speaker Change: <unk> of those partners will become evident.

Speaker Change: Okay.

Speaker Change: So first on the second part of your question there, 100% I mean, we are working with these partners and they are working with us because they're excited about what we're doing and they want to see it in the operating room and be able to use that in the operating room.

Speaker Change: And this is a market that is 96% white space that has incredible opportunity and not nearly enough surgical robotics or robots out in the field today.

Speaker Change: Which gives these hospital systems, the opportunity and you'd be availability to purchase our system. When we're on market because of its differentiation and the promise of visualization dexterity sensing capabilities and ability to operate at.

Adam Sachs: To answer directly about what we're working on with them. Especially with the latest system with UMass, it's primarily focused around paraoperative workflow and procedures. Really making sure not only that we've designed a system that is excellent for workflow and able to do procedures in an efficient, streamlined manner, but on top of that, that we're actually designing the workflow around the system and around what makes sense for the operating room today. That makes sense. Thank you for the question. Yeah, thank you. Thank you, and as a final reminder, if you would like to ask a question, please press star, followed by one on your telephone keypad.

Speaker Change: To answer directly about what we're working on with them.

Speaker Change: Especially with the latest system with Umass, it's primarily focused around para operative a workflow and procedures are really making sure not only that we've designed a system that is is excellent for workflow enabled to do procedures in an efficient streamlined manner, but.

Speaker Change: On top of that that we're actually designing the workflow around the system and around what makes sense for the operating room today.

Speaker Change: That makes sense. Thank you for the questions.

Speaker Change: Yeah. Thank you.

Speaker Change: Thank you and as a final reminder, if you would like to ask a question. Please press star followed by one on the telephone keypad will pool, so just a moment.

Nadia: We'll pause for just a moment.

Adam Sachs: If you have no further questions, I'll hand back to Adam for any closing comments. I appreciate the questions everybody.

Adam: It appears you have nice I had a question so I'll hand back to Adam for any closing comments.

Speaker Change: Yeah.

Adam: I appreciate the questions everybody with that that concludes the call. Thank you.

Nadia: With that, that concludes the call. Thank you. Thank you, this concludes today's call.

Speaker Change: Yeah.

Speaker Change: Thank you. This concludes today's call. Thank you for joining you may now disconnect your lines.

Nadia: Thank you for joining, you may now disconnect your line.

Speaker Change: Okay.

Speaker Change: [music].

Speaker Change: Yes.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: [noise].

Speaker Change: Yeah.

Speaker Change: Okay.

Okay.

Speaker Change: Okay.

Speaker Change: Okay.

Speaker Change: Right.

Speaker Change: Yeah.

Speaker Change: Yeah.